In high income countries, biomarkers such as C-reactive protein (CRP) and procalcitonin, have been shown to be safe, cost-effective, and improve correct antibiotic use in the management of respiratory tract infections in primary care settings [17, 25, 54]. This evidence concerns the gene CRP and Respiratory tract infection.